EUCTR2014-002613-31-GB进行中（未招募）不适用
A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers. - TORCMEK
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 118
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Written informed consent prior to admission to this study
- •2) Age =18 years
- •3) ECOG performance status 0 or 1
- •4) Life expectancy = 12 weeks
- •5) Patients must have been at least one lesion, not previously irradiated, that can be measured accurately at baseline as =10mm in the longest diameter (except lymph nodes which must have short axis =15mm) with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeatede measurements
- •6) Radiological or clinical evidence of disease progression
- •7) Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing
- •8) Adequate haematologic and end organ function, defined by laboratory results obtained within 14 days prior to the first study treatment
- •9) Female patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception beginning 2 weeks before the first dose of investigational product and for 30 days after the final dose of investigational product. Male patients must agree to use appropriate contraception during the trial and for 3 months afterwards
- •Criteria unique to the Dose Escalation Part (Phase 1b part):
- •1) Histologically or cytologically advanced solid tumour; the study will be limited to
- •a) tumour types with frequent activation of MAPK and/or PI3K pathways (pancreatic, thyroid, endometrial, renal, breast or ovarian carcinoma, colorectal cancer, NSCLC or melanoma
- •b) tumours with known alteration in =1 gene involved in PI3K/AKT/mTOR or Ras/MEK pathway signalling, such as KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR, FGFR, HER2, MET, RET, KIT
- •2) Metastatic or locally advanced disease, which is refractory to conventional treatment or for which no conventional therapy exists; locally recurrent disease must not be amenable to resection with curative intent
- •Criteria unique to the lung cancer dose expansion cohorts (phase IIa part):
- •1) Histologically confirmed non-small cell lung cancer
- •2) Stage III disease that is unsuitable to radio-chemotherapy or Stage IV disease or recurrent NSCLC; recurrent disease must not be amenable to resection or radical radiotherapy with curative intent
- •3) Prior chemotherapy and/or, if indicated/accessible, EGFR-directed or ALK-directed therapy for advanced disease
- •Criteria unique to the triple-negative breast cancer dose expansion cohort (phase IIa):
- •1) Histologically confirmed triple negative breast cancer
- •2) Metastatic or locally recurrent disease; locally recurrent disease must not be amenable to resection with curative intent
- •3) Prior chemotherapy for advanced disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 118
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1) Symptomatic CNS involvement or CNS involvement requiring steroid therapy; patients with treated brain metastases that are asymptomatic and have been clinically stable for 1 month will be eligible for protocol participation
- •2) Prior chemotherapy, biological therapy, radiation therapy, immunotherapy, other anticancer agents and any investigational agents within 14 days of starting study treatment
- •3) Any unresolved toxicity > CTCAE Grade 1 from previous anti-cancer therapy
- •4) Current refractory nausea and vomiting, chronic gastrointestinal disease or inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of the study medication
- •5) Significant cardiovascular disease
- •6) QTc prolongation defined as a QTc interval >470msecs
- •7) Concomitant medications known to prolong QT interval
- •8) Patients receiving concomitant immunosuppressive agents or chronic systemic corticosteroids for =28 days at the time of study entry
- •9)Evidence of interstitial fibrotic lung disease (bilateral, diffuse, parenchymal lung disease)
- •10) Clinically significant abnormalities of glucose metabolism
- •11) Opthalmological conditions as follows:
- •a) Intra-ocular pressure >21mmHg, or uncontrolled glaucoma
- •b) Current or past history of central serous retinopathy or retinal vein occlusion
- •12) Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout period before the first dose of study treatment
- •13) Exposure to potent or moderate inhibitors or inducers of CYP2C8 within the stated washout periods before the first dose of study treatment
- •14) Exposure to sensitive or narrow therapeutic range substrates of the drug metabolising enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp and BCRP within the appropriate wsh-out period before the first dose of study treatment
- •15) Active second malignancy (except non-melanomatous skin cancer); active secondary malignancy is defined as a current need for cancer therapy or a high possibility of recurrence during the study
- •16) Any evidence or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
- •17) Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that in the investigators opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent
- •18) Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol
- •19) Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry
- •Criteria specific to dose expansion cohorts:
- •1) Prior treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitors or MEK, Ras or Raf inhibitors
- •2) Prior radiotherapy to the indicator lesion(s); newly arising lesions in previously irradiated areas are accepted
研究者
相似试验
已完成
1 期
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerAdvanced Metastatic Breast CancerNCT01597388AstraZeneca99
进行中（未招募）
不适用
A Phase I/IIa Study of AZD4547 in combination with cisplatin and capecitabineStage 1 - Patients with advanced solid tumours.Stage 2 - Histologically proven adenocarcinoma or undifferentiated carcinoma of the oesophagus, gastro-oesophageal junction, or stomach.MedDRA version: 16.0Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10030139Term: Oesophageal adenocarcinoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10060139Term: Antineutrophil cytoplasmic antibody decreasedSystem Organ Class: 10022891 - InvestigationsMedDRA version: 16.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000642-37-GBGreater Glasgow Health Board158
已完成
1 期
A trial of AZD4547 in combination with cisplatin and capecitabineNeoplasmsCancerISRCTN66171897HS Greater Glasgow and Clyde (UK)158
撤回
不适用
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)NeoplasmsKCT0003954Samsung Medical Center27
招募中
不适用
Study of AZD1775 in combination with paclitaxel, in advanced gastric adenocarcinoma patients harboring TP53 mutation as a second-line chemotherapyNeoplasmsKCT0004071Samsung Medical Center25